Please login to the form below

Not currently logged in
Email:
Password:

relugolix

This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer. Myovant is locked in a battle with AbbVie for women’s health applications of its GnRH inhibitor relugolix, but a ... The phase 3 HERO trial of Takeda-partnered relugolix has

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics